

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 13-3-2008

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 26-1-2008 TO BE PUBLISHED ON 14-3-2008 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

65/2008	<u>21-1-2008</u> Novartis AG, Switzerland (Priority 22-1-07 EP)	“Benzoquinazolone derivatives”
66/2008	<u>22-1-2008</u> Glaxo Group Limited, United Kingdom (Priority 24-1-07 GB)	“Novel Device”
67/2008	AstraZeneca AB, Sweden (Priority 25-1-07 US)	“Chemical compounds”
68/2008	Bayer CropScience AG, Germany (Priority 02-2-07 EP)	“Synergistic fungicidal active compound combinations”
69/2008	IRM LLC, Bermuda (Priority 02-2-07 USA)	Compounds and compositions as modulators of GPR119 activity”
70/2008	<u>23-1-2008</u> Syngenta Participations AG, Switzerland (Priority 15-2-07 Europe)	“Chemical Compounds”
71/2008	<u>24-1-2008</u> Mochida Pharmaceutical Co. Ltd., Japan (Priority 24-1-07 Japan)	“Heterocyclidene-N-(ARYL) acetamide derivative”
72/2008	Theravance, Inc, USA (Priority 02-2-07 USA)	“Dual-acting antihypertensive agents”
73/2008	Merck and Co., Inc USA (Priority 31-1-07 US)	“ Substituted pyrano[2,3-B] pyridine derivatives as cannabinoid-1 receptor modulators”
74/2008	SmithKline Beecham Corporation USA (Priority 26-1-07 US)	“Anthranilamide inhibitors of autora kinase”
75/2008	Sanofi-Aventis France (Priority 26-1-07 Germany)	“ Phenothiazine derivatives, process for their preparation and their use as pharmaceuticals”
76/2008	<u>26-1-2008</u> Eisai R&D Management Co. Ltd, Japan (Priority 29-1-07 Japan)	“ Macrolide compound in solid form, process for preparation thereof, and pharmaceutical compositions containing the same”

77/2008

1.Syngenta Participations AG,
Switzerland
2. Syngenta Limited,
United Kingdom
(Priority 29-1-07 Switzerland)

“Herbicidal Composition”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

1009/2004 LES Laboratoires Servier “Miatrrix tablet enabling prolonged release of
France gliclazide after administration by the oral route”

(INT: CL, A61K, 9/26)

139339

The invention relates to a matrix tablet for the prolonged release of gliclazide which ensures continuous and consistent release of the active ingredient after administration by the oral route, the release being insensitive to variations in the pH of the dissolution medium.

1012/2004 LES Laboratoires Servier “Arginine salt of perindopril and a
France pharmaceutical composition comprising thereof”

(INT: CL, A61K, 31/404, C07D, 209/42)

139340

The present invention relates to a new salt of perindopril and to pharmaceutical compositions containing it.


59/2005 Otsuka Pharmaceutical
Co., Ltd.
Japan

“Method for producing 4-nitroimidazole
compound”

(C07D, 233/92)


139341

The present invention provides a method for producing a 4-nitroimidazole compound represented by general formula (1) at high yield and at high purity by a safe method causing few dangers such as explosion. The production method of the present invention comprises iodinating a 4-nitroimidazole compound represented by general formula (2) :



Wherein each of X1 and X2 represents a chlorine atom or bromine atom, and then reducing the obtained 5-iodo-4-nitroimidazole compound represented by general formula (3):

(3) :




128/2005 LES Laboratoires Servier
France

Wherein X2 is the same as defined above.
“A process for the syntheses of IV abradine”

(INT: CL, C07D, 223/16)

139342

Process for the synthesis of iv abradine of formula (1) :



Addition salts thereof with a pharmaceutically acceptable acid, and hydrates thereof, a crystalline form of iv abradine hydrochloride.

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139246	F. Hoffmann-La Roche AG, Switzerland	84/1998
139247	Bristol-Myers Squibb Company, USA	125/1998
139248	The Procter & Gamble Co., USA	587/1998
139249	Dainippon Sumitomo Pharma co., Ltd. Japan	664/1998
139250	Sumitomo Chemical Company, Limited, Japan	503/2001
139251	Sumitomo Chemical Company, Limited, Japan	852/2001
139252	Pfizer Products Inc. USA	396/2002
139253	Professor Dr. Siegfried Peter, Germany	264/2005
139254	Pfizer Inc. USA	520/1996
139255	SmithKline Beecham Biological s.a. Belgium	334/1999
139256	Warner-Lambert Company, USA	465/1999
139257	Merck Patent Gesellschaft Mit beschränkter Haftung Darmstadt, Germany	794/1999
139258	The Procter & Gamble Co., USA	820/2002
139259	Pfizer Inc. USA	296/1997
139260	SmithKline Beecham Plc. U.K.	839/1998

139261	Merck Patent Gesellschaft Mit Beschränkter Haftung Darmstadt, Germany	88/1999
139262	Pfizer Products Inc. USA	497/1999
139263	Pfizer Products Inc. USA	867/1999
139264	Novartis AG, Switzerland	849/2001
139265	Pfizer Products Inc. USA	297/2005
139266	Pfizer Research and Development Company, N.V/S.A. Ireland	1092/1998
139267	Merck & Co., Inc. USA	71/2003
139268	H. A. Khan, Musarrat A, Azam H. Shah, Huma. S, Dr. Rabia Zubari, PCSIR, Karachi, Pakistan	928/2004
139269	Pfizer Inc., USA	28/2005
139270	Sanofi, France	320/98
139271	Bristol-Myers Squibb Company USA	440/2000
139272	Bristol-Myers Squibb Company USA	609/2003
139273	Bayer HealthCare AG Germany	19/2005
139274	Pfizer Products Inc. USA	892/98
139275	Pfizer Products Inc. USA	420/2007
139276	Pfizer Products Inc. USA	515/99
139277	Pfizer Products Inc. USA	467/2000
139278	Aventis Pharma S.A. France	49/2003

139279	Chiesi Pharmaceutici SPA Italy	156/2003
139280	1. Insignion Holdings Limited, Bermuda 2. Veritron Limited United Kingdom	473/2003
139281	Chiesi Pharmaceutici SPA Italy	687/2002
139282	Bayer Pharmaceuticals Corporation USA	663/2003
139283	Dressel Pte. Ltd. Singapore.	1243/2005
139284	Pfizer Products Inc, USA	937/2003

(Mrs. Yasmeen Abbasi)
Controller of Patents
Tel: 9215488